Floatz logo

rg4733

Conjunctival Kaposi Sarcoma

National Cancer Institute (NCI)Phase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Conjunctival Kaposi Sarcoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
L19IL2/L19TNF
Philogen S.p.A.
Phase 2CCC
Gdc-0449
National Cancer Institute (NCI)
Phase 1/2CCC
Sgn-30
Phase 1/2CCC
cd146/her2 car-t cells
Essen Biotech
Phase 1/2CCC

View all 14 →

Same molecule, other indications

rg4733 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
melanomaDormant
CCC
Indicative ·
51 / 100
View asset →
Stage IV Skin MelanomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →